Old dog, new tricks: Polydatin as a multitarget agent for current diseases.

Area of Science:

• Pharmacology and Natural Products Research
• Cardiovascular and Metabolic Diseases
• Molecular Biology and Cellular Mechanisms

Background:

• Polydatin (PD) is a natural compound from Polygonum cuspidatum with documented biological activities.
• Recent research since 2014 has highlighted PD's potential, but a comprehensive review is lacking.
• A significant gap exists between understanding PD's biological effects and its drug development.

Purpose of the Study:

• To comprehensively summarize recent findings on the pharmacological effects of Polydatin (PD).
• To classify these effects based on specific diseases and underlying mechanisms of action.
• To identify potential future therapeutic applications for PD.

Main Methods:

• Literature review and classification of recent studies on Polydatin (PD).
• Analysis of PD's therapeutic roles across various disease models.
• Identification and categorization of PD's primary mechanisms of action.

Main Results:

• Polydatin (PD) demonstrates therapeutic effects in a range of diseases.
• Key mechanisms include antioxidative, anti-inflammatory, autophagy/apoptosis regulation, mitochondrial function maintenance, and lipid regulation.
• PD shows promise for cardiac and cerebral ischemia/reperfusion diseases and atherosclerosis.

Conclusions:

• Polydatin (PD) exhibits broad therapeutic potential through multiple molecular mechanisms.
• Further research into PD's pharmacological effects is warranted for drug development.
• PD is a promising candidate for treating cardiovascular diseases and atherosclerosis.